Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

TG Therapeutics ( (TGTX)) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG Therapeutics is a biopharmaceutical company focused on ...

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price target of $38.00. Mayank Mamtani’s rating is based on TG ...

TG Therapeutics develops treatments for B-cell diseases, with a primary focus on multiple sclerosis. Its lead product, Briumvi, serves as the cornerstone of its commercial success. Briumvi ...

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics plans to modify the ratio of its American Depositary Shares (ADS) to improve its trading price on Nasdaq, with the new ratio ...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a recent move, Carl Dambkowski, Chief Medical Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), sold a significant amount of company stock, totaling over... Apogee (NASDAQ ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company, announced today that its Phase 1 clinical trial will progress to the second cohort of patients. This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year. The AI effect in pharma commercial ...

Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring ...